Ventyx Biosciences, Inc. $VTYX Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 8.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 945,206 shares of the company’s stock after purchasing an additional 73,601 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 1.33% of Ventyx Biosciences worth $2,023,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new stake in Ventyx Biosciences in the second quarter valued at approximately $71,000. Nuveen LLC purchased a new stake in Ventyx Biosciences in the 1st quarter valued at $194,000. Ieq Capital LLC acquired a new stake in Ventyx Biosciences during the 1st quarter worth $223,000. Pallas Capital Advisors LLC purchased a new position in Ventyx Biosciences during the 2nd quarter worth $38,000. Finally, Redmile Group LLC increased its stake in Ventyx Biosciences by 1,164.1% in the first quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock valued at $1,805,000 after purchasing an additional 1,445,615 shares during the period. 97.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on VTYX. Oppenheimer upped their price objective on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company lifted their price objective on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, November 7th. HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Ventyx Biosciences Price Performance

VTYX stock opened at $9.25 on Monday. The company’s 50 day simple moving average is $4.90 and its 200-day simple moving average is $3.22. Ventyx Biosciences, Inc. has a 12 month low of $0.78 and a 12 month high of $9.99. The firm has a market capitalization of $660.08 million, a PE ratio of -6.17 and a beta of 1.21.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. As a group, sell-side analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.